Who is eligible for clinical trial NCT06422884?

Participants must meet protocol criteria for Idiopathic Pulmonary Fibrosis. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06422884 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-02-20

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) (NCT06422884)

A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Endeavor Biomedicines, Inc.

🩺 Plain-English Summary (8th-Grade Level)

The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.

Who can join: Review the eligibility criteria below.

Location: Research Site — Quilmes, Buenos Aires

Age range: 40 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (78 Sites)

Showing the first 25 of 78 sites.

Research Site — Quilmes, Buenos Aires
Research Site — Buenos Aires,
Research Site — Buenos Aires,
Research Site — Mendoza,
Research Site — Mendoza,
Research Site — Camperdown, New South Wales
Research Site — Macquarie Park, New South Wales
Research Site — Brisbane, Queensland
Research Site — South Brisbane, Queensland
Research Site — Box Hill, Victoria
Research Site — Nedlands, Western Australia
Research Site — Graz, Styria
Research Site — Vienna,
Research Site — Dinant, Namur
Research Site — Brussels,
Research Site — Brussels,
Research Site — Edmonton, Alberta
Research Site — Vancouver, British Columbia
Research Site — Ajax, Ontario
Research Site — Montreal, Quebec
Research Site — Sherbrooke, Quebec
Research Site — Trois-Rivières, Quebec
Research Site — Angers,
Research Site — Bordeaux,
Research Site — Caen,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Idiopathic Pulmonary Fibrosis

Atezolizumab for Idiopathic Pulmonary Fibrosis — Los Angeles, California
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis — Birmingham, Alabama
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) — Birmingham, Alabama
Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis — Seattle, Washington
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) — Camperdown, New South Wales

Explore by condition: All Idiopathic Pulmonary Fibrosis clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗